Revenue
No reported data
Silexion Therapeutics Corp (SLXN)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $7.1M | $5.8M | $3.7M |
| Operating expenses | $11.6M | $12.6M | $4.7M |
| Operating income | −$11.6M | −$12.6M | −$4.7M |
| Net income | −$11.9M | −$16.5M | −$5.1M |
| Basic EPSper diluted share | $8.96 | $394.94 | $44.23 |
| Diluted EPSper diluted share | $8.96 | $394.94 | $44.23 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 26, 2026Form 4 | Shirvan MitchellCSO and CDO | SellOrdinary Shares | 22.8K | $1.36 | $31.0K | 27.9K |